SLIDE 1
The Future of Medical Cannabis Catherine Jacobson, PhD Director, - - PowerPoint PPT Presentation
The Future of Medical Cannabis Catherine Jacobson, PhD Director, - - PowerPoint PPT Presentation
The Future of Medical Cannabis Catherine Jacobson, PhD Director, Clinical Research The Current System Fails Patients The Current System Fails Patients State-based Medical FDA and DEA approved Cannabis Regulations pharmaceutical products
SLIDE 2
SLIDE 3
FDA and DEA approved pharmaceutical products Accessibility Insurance Coverage/Cost State-based Medical Cannabis Regulations Safety & Reliability of Products Appropriate Medical Supervision
The Current System Fails Patients
ISSUES
SLIDE 4
Expanding Access
Patients with epilepsy (3 million in the US)
Accessing cannabis-derived products Not accessing from medical cannabis-derived products
SLIDE 5
Clinical Data
Safe Dose and Titration Schedule Basic Safety Profjle in Their Patient Population Adverse Events Side Effects Profjle Drug-drug Interactions Expected Outcomes
SLIDE 6
Medical Preparations
Meet GMP Standards to Ensure Safety Reliable and Reproducible Chemically Defjned
SLIDE 7
Global Access
Current Spectrum of Regulations
Legal / Essentially Legal Legal (Medical Only) Decriminalized Illegal But Often Unenforced Illegal No Information
SLIDE 8
Tilray—Federally Licensed in Canada
GMP-grade Cannabis Clinical T rial-grade GMP-grade Cannabis-derived Extracts
SLIDE 9
Phase 2/3 T rial in partnership with the University of Sydney, Australia for chemotherapy-induced nausea and vomiting Phase 2/3 T rial in partnership with the Ontario Brain Institute, Canada for adult refractory epilepsy Open-label trials provide immediate patient access for specifjc indications Database: dose, side effects, indications, adverse events
The Path Forward—Clinical Research
SLIDE 10
Thank Y
- u